Executive Dysfunction in MCI: Subtype or Early Symptom

Overview

Journal Int J Alzheimers Dis

Publisher Wiley

Date 2012 Jun 14

PMID 22693679

Citations 29

Authors

Ivar Reinvang

Ramune Grambaite

Thomas Espeseth

Affiliations

Soon will be listed here.

Abstract

Mild cognitive impairment (MCI) may take several forms, and amnestic MCI (aMCI) has been recognized as an early stage of Alzheimer's Disease (AD). Impairment in executive functions including attention (eMCI) may be indicative of several neurodegenerative conditions. Executive impairment is frequently found in aMCI, it is significant for prognosis, and patients with eMCI may go on to develop AD. Recent studies have found changes in white matter integrity in patients with eMCI to be more sensitive than measures of cortical atrophy. Studies of genetic high-risk groups using sensitive cognitive neuroscience paradigms indicate that changes in executive function may be a cognitive marker useful for tracking development in an AD pathophysiological process.

Citing Articles

COVID-19 Exacerbates Neurovascular Uncoupling and Contributes to Endothelial Dysfunction in Patients with Mild Cognitive Impairment.

Owens C, Pinto C, Szarvas Z, Muranyi M, Pinaffi-Langley A, Peterfi A Biomolecules. 2025; 14(12.

PMID: 39766328 PMC: 11726736. DOI: 10.3390/biom14121621.

Neurovascular coupling, functional connectivity, and cerebrovascular endothelial extracellular vesicles as biomarkers of mild cognitive impairment.

Owens C, Pinto C, Mukli P, Gulej R, Velez F, Detwiler S Alzheimers Dement. 2024; 20(8):5590-5606.

PMID: 38958537 PMC: 11350141. DOI: 10.1002/alz.14072.

A Comparative Evaluation of Error Processing Performance and its Relationship with Cognitive Function in Patients with Alzheimer's Disease, Individuals with Mild Cognitive Impairment, and Normal Controls Using the Event-Related Potentials.

Hedayatjoo M, Tehrani-Doost M, Vahabi Z, Akbarfahimi M, Khosrowabadi R J Alzheimers Dis Rep. 2024; 8(1):681-696.

PMID: 38746624 PMC: 11091745. DOI: 10.3233/ADR-230104.

Non-equivalence of sub-tasks of the Rey-Osterrieth Complex Figure Test with convolutional neural networks to discriminate mild cognitive impairment.

Park J BMC Psychiatry. 2024; 24(1):166.

PMID: 38413893 PMC: 10900783. DOI: 10.1186/s12888-024-05622-5.

Early postoperative neurocognitive complications in elderly patients: comparing those with and without preexisting mild cognitive impairment- a prospective study.

Somnuke P, Srishewachart P, Jiraphorncharas C, Khempetch A, Weeranithan J, Suraarunsumrit P BMC Geriatr. 2024; 24(1):84.

PMID: 38253999 PMC: 10804619. DOI: 10.1186/s12877-024-04663-5.

References

Grambaite R, Selnes P, Reinvang I, Aarsland D, Hessen E, Gjerstad L . Executive dysfunction in mild cognitive impairment is associated with changes in frontal and cingulate white matter tracts. J Alzheimers Dis. 2011; 27(2):453-62. DOI: 10.3233/JAD-2011-110290. View

Reinvang I, Espeseth T, Gjerstad L . Cognitive ERPs are related to ApoE allelic variation in mildly cognitively impaired patients. Neurosci Lett. 2005; 382(3):346-51. DOI: 10.1016/j.neulet.2005.03.024. View

Grau-Olivares M, Arboix A . Mild cognitive impairment in stroke patients with ischemic cerebral small-vessel disease: a forerunner of vascular dementia?. Expert Rev Neurother. 2009; 9(8):1201-17. DOI: 10.1586/ern.09.73. View

Petersen R, Doody R, Kurz A, Mohs R, Morris J, Rabins P . Current concepts in mild cognitive impairment. Arch Neurol. 2001; 58(12):1985-92. DOI: 10.1001/archneur.58.12.1985. View

Collette F, Hogge M, Salmon E, van der Linden M . Exploration of the neural substrates of executive functioning by functional neuroimaging. Neuroscience. 2005; 139(1):209-21. DOI: 10.1016/j.neuroscience.2005.05.035. View

Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C . Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiol Aging. 2010; 32(12):2320.e15-32. DOI: 10.1016/j.neurobiolaging.2010.04.028. View

Fratiglioni L, Launer L, Andersen K, Breteler M, Copeland J, Dartigues J . Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54(11 Suppl 5):S10-5. View

Espeseth T, Greenwood P, Reinvang I, Fjell A, Walhovd K, Westlye L . Interactive effects of APOE and CHRNA4 on attention and white matter volume in healthy middle-aged and older adults. Cogn Affect Behav Neurosci. 2006; 6(1):31-43. DOI: 10.3758/cabn.6.1.31. View

Reinvang I, Winjevoll I, Rootwelt H, Espeseth T . Working memory deficits in healthy APOE epsilon 4 carriers. Neuropsychologia. 2009; 48(2):566-73. DOI: 10.1016/j.neuropsychologia.2009.10.018. View

10.

Rosen H, Lengenfelder J, Miller B . Frontotemporal dementia. Neurol Clin. 2000; 18(4):979-92. DOI: 10.1016/s0733-8619(05)70235-8. View

11.

Winterer G, Musso F, Konrad A, Vucurevic G, Stoeter P, Sander T . Association of attentional network function with exon 5 variations of the CHRNA4 gene. Hum Mol Genet. 2007; 16(18):2165-74. DOI: 10.1093/hmg/ddm168. View

12.

Albert M, Blacker D, Moss M, Tanzi R, McArdle J . Longitudinal change in cognitive performance among individuals with mild cognitive impairment. Neuropsychology. 2007; 21(2):158-69. DOI: 10.1037/0894-4105.21.2.158. View

13.

Whitwell J, Petersen R, Negash S, Weigand S, Kantarci K, Ivnik R . Patterns of atrophy differ among specific subtypes of mild cognitive impairment. Arch Neurol. 2007; 64(8):1130-8. PMC: 2735186. DOI: 10.1001/archneur.64.8.1130. View

14.

Wisdom N, Callahan J, Hawkins K . The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Neurobiol Aging. 2009; 32(1):63-74. DOI: 10.1016/j.neurobiolaging.2009.02.003. View

15.

Greenwood P, Sundararajan R, Lin M, Kumar R, Fryxell K, Parasuraman R . Both a nicotinic single nucleotide polymorphism (SNP) and a noradrenergic SNP modulate working memory performance when attention is manipulated. J Cogn Neurosci. 2008; 21(11):2139-53. PMC: 2866643. DOI: 10.1162/jocn.2008.21164. View

16.

Carter C, Barch D . Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull. 2007; 33(5):1131-7. PMC: 2632368. DOI: 10.1093/schbul/sbm081. View

17.

Johnson J, Vogt B, Kim R, Cotman C, Head E . Isolated executive impairment and associated frontal neuropathology. Dement Geriatr Cogn Disord. 2004; 17(4):360-7. PMC: 2637356. DOI: 10.1159/000078183. View

18.

Gomar J, Bobes-Bascaran M, Conejero-Goldberg C, Davies P, Goldberg T . Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry. 2011; 68(9):961-9. DOI: 10.1001/archgenpsychiatry.2011.96. View

19.

Sjobeck M, Elfgren C, Larsson E, Brockstedt S, Latt J, Englund E . Alzheimer's disease (AD) and executive dysfunction. A case-control study on the significance of frontal white matter changes detected by diffusion tensor imaging (DTI). Arch Gerontol Geriatr. 2009; 50(3):260-6. DOI: 10.1016/j.archger.2009.03.014. View

20.

Albert M, DeKosky S, Dickson D, Dubois B, Feldman H, Fox N . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):270-9. PMC: 3312027. DOI: 10.1016/j.jalz.2011.03.008. View